Prognostic Factors in Solitary Plasmacytoma of the Bone
Author Information
Author(s): David Knobel, Abderrahim Zouhair, Richard W. Tsang, Philip Poortmans, Yazid Belkacémi, Michel Bolla, Fazilet Dinçbas Oner, Christine Landmann, Bernard Castelain, Mahmut Ozsahin
Primary Institution: Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Hypothesis
What are the prognostic factors and optimal radiation therapy dose for patients with solitary plasmacytoma?
Conclusion
Younger patients, especially those with vertebral localization, have the best outcomes when treated with moderate-dose radiation therapy.
Supporting Evidence
- The 5-year overall survival rate was 70%.
- Patients with tumors less than 5 cm had better outcomes.
- Older age was a predictor for progression to multiple myeloma.
- Local control was 88% at 5 years.
- Median follow-up was 54 months.
Takeaway
This study looked at patients with a rare bone cancer called solitary plasmacytoma and found that younger patients tend to do better with treatment.
Methodology
Data from 206 patients treated for solitary plasmacytoma were collected and analyzed for survival, disease-free survival, and local control.
Potential Biases
Potential biases due to the retrospective nature of the study and varying treatment protocols across centers.
Limitations
The study is retrospective and may not account for all variables affecting outcomes.
Participant Demographics
Median age was 60 years, with a male-to-female ratio of 1.82.
Statistical Information
P-Value
p<0.00001 for younger age affecting overall survival.
Confidence Interval
95% CI: 63–77 for overall survival.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website